Trial Profile
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered NEV801 in Subjects With Advanced Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Camptothecin/podophyllotoxin (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors Neovia Oncology
- 02 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 02 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 11 Sep 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.